Celltrion's (KRX:068270) Steqeyma, or ustekinumab-stba, a biosimilar to Stelara (ustekinumab) was added to the Costco Member Prescription Program to improve access to costly inflammatory disease treatments.
Steqeyma is used to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults and select pediatric patients. The drug is available as a subcutaneous injection and intravenous infusion, Celltrion said last week.
Costco members, including self-funded employer plans and uninsured individuals, gained access to the biosimilar through Costco Specialty Pharmacies from April 1.
Shares of Celltrion rose more than 1% in recent trade on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.